Much has been said of the market prospect for Epidiolex from GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH). It was even covered in detail at the analyst call after the recent 4Q2016 results. Unfortunately, all the excitement over the “Epidiolex” potential in the cure of childhood epilepsies has blinded the industry to the potential for other cannabinoid therapies under development by the firm. The dollar potential appears far superior than the budding orphan designation therapies approved by the FDA so far.
GW Pharmaceuticals’ focus on the therapeutic use of a wide range of patented cannabinoids puts it in a strong position. Development by other medicinal marijuana firms, especially Insys Therapeutics (NASDAQ:INSY), highlights what is budding in this expanding industry.
There is lot more potential for this medication in childhood epilepsies. Adequate to say that street analysts gave it sales targets in a range of $800 million to 3 billion. The latest projection given was from Cowen who stated the figure at $1 billion every year by 2021.
What has been fairly under-appreciated is this medicine’s potential to be utilized for adult epilepsy. There are outstanding previous illustrations of where a medication permitted for a minority orphan designation application and then gets fast-tracked by the U.S. FDA for a wider usage.
In the instance of epilepsy, there are anticipated to be 5 million senior sufferers in the U.S., and 500,000 in the United Kingdom alone. Current epilepsy cures are all unsatisfactory, thus “Epidiolex” could have extensive potential in this field.
At the experts results briefing, the CMO Dr Steven Wright provided some extra test details. Besides from epilepsy, the medication is also at Stage III study for tuberous sclerosis complex. It is a genetic brain cancer problem thought to impact 40,000 people in the U.S. and 1-2 million worldwide.
The medication is also at Stage III for Infantile Spasms, added rare type of childhood epilepsy. It has nearly 1,000-2,000 new instances each year in the U.S.